Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Ranibizumab Market Growth From $2.86 Billion In 2026 To $3.3 Billion By 2030 At A CAGR Of 3.6%
The ranibizumab market size has shown consistent expansion in recent years. This market is expected to increase from $2.76 billion in 2025 to $2.87 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.0%. Historically, this growth has been driven by factors including the rising prevalence of age-related macular degeneration, the clinical validation of anti-VEGF therapy’s effectiveness, the increasing incidence of diabetic retinopathy, enhancements in diagnostic imaging for retinal disorders, and the early regulatory approvals received for ranibizumab.
The ranibizumab market is anticipated to experience consistent expansion in the coming years. It is projected to reach $3.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.6%. Factors contributing to this growth include a globally expanding aging population, an increase in worldwide diabetes prevalence, broader availability of advanced ophthalmic care, a rise in the use of intravitreal injections, and continuous enhancements in retinal disease screening efforts. Significant trends during this period encompass a surge in the adoption of anti-VEGF therapies for retinal conditions, a developing preference for prefilled syringe formulations, a greater need for treating diabetic eye disorders, an increase in specialized ophthalmology care facilities, and enhanced application of long-term maintenance therapy for chronic retinal diseases.
Get A Free Sample Report With In-Depth Market Insights:
Ranibizumab Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The expanding occurrence of eye conditions is projected to boost the growth of the ranibizumab market in the coming years. Eye diseases encompass a variety of ailments that affect the eyes, potentially leading to impaired vision and ocular health. The increasing prevalence of these conditions is attributed to factors such as aging populations, changes in lifestyle, and a rise in chronic illnesses like diabetes. Ranibizumab is utilized in the treatment of conditions such as age-related macular degeneration and diabetic retinopathy, thereby aiding in the reduction of vision impairment amidst the growing prevalence of eye diseases. For instance, in August 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately 2.2 billion people globally experience either near or distance vision impairment. Therefore, the escalating prevalence of eye diseases will propel the growth of the ranibizumab market.
Ranibizumab Market Segment Landscape: Which Areas Lead Development?
The ranibizumab market covered in this report is segmented –
1) By Product: Single Use Prefilled Syringe, Single Use Glass Vial
2) By Application: Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), Retinal Vein Occlusion (RVO)
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Single Use Prefilled Syringe: 0.3 Ml Syringe, 0.5 Ml Syringe, 1 Ml Syringe, Other Volume Variants
2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial, 1.0 Mg Or 0.1 Ml Vial, 2.0 Mg Or 0.2 Ml Vial, Other Volume Variants
Ranibizumab Market Innovation Trends Shaping Future Development
Companies primarily engaged in the ranibizumab market are increasingly concentrating on cost-effective therapeutic options, such as ranibizumab biosimilars, aimed at treating and preventing vision impairment in patients with retinal disorders. A ranibizumab biosimilar is a biological medicine that exhibits high similarity to the original ranibizumab, yet it is marketed under a distinct brand name, thereby providing a more affordable alternative while ensuring comparable efficacy and safety profiles. For example, in April 2024, Formycon AG, a biotechnology company from Germany, and Bioeq AG, a biopharmaceutical company based in Switzerland, jointly announced the commercial launch of FYB201, a biosimilar to Lucentis (Ranibizumab), in Canada and Switzerland. This introduction followed the receipt of marketing authorization from Health Canada, under the brand name Ranopto, and from Swissmedic, under the brand name Ranivisio. FYB201 offers a new, high-quality, effective, and affordable treatment solution for individuals suffering from severe retinal diseases, having already established its importance as a cost-effective treatment option for patients in the USA and various parts of Europe.
Ranibizumab Market Industry Leaders And Competitive Landscape
Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Genentech Inc., Bayer AG, Novartis AG, Biocon Limited, Samsung Biologics Co Ltd, Celltrion Healthcare Co Ltd, Formycon AG, Coherus BioSciences Inc, Xbrane Biopharma AB, Alvotech, Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, Enzene Biosciences Ltd, Amman Pharmaceutical Industries
View The Full Ranibizumab Market Report:
Ranibizumab Market Geographic Spread And Regional Opportunities
North America was the largest region in the ranibizumab market in 2025. The regions covered in the ranibizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model